Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
- Delay Reimbursement Fee Revisions by Few Months: LDP Project Team
April 21, 2023
- Health Minister Negative about Fee Premiums for Use of Japan-Made Drugs
April 20, 2023
- Japan to End Priority Review for COVID Drugs and Vaccines after Severity Downgrade: Official
April 20, 2023
- Industry Groups Call for Reimbursement Scheme Tailored to Characteristics of SaMDs
April 19, 2023
- Push SaMDs from Industrial Policy Viewpoint: Deregulation Panel Member
April 18, 2023
- Wholesaler Lobby Raps Politicians over Product Coverage of Off-Year Cuts
April 18, 2023
- LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Expert Panel Proposal to Be Compiled at May-End: MHLW Official
April 18, 2023
- Relief Claims OK’ed for 12 More Deaths Possibly Linked to COVID Jabs
April 18, 2023
- Comprehensive Review of COVID Budgets Necessary: MOF Panel Chair
April 17, 2023
- Japan to Set Out Measures Against Hay Fever, Promote Curative Therapy
April 17, 2023
- Number of Mpox Cases Totals 109 in Japan: MHLW
April 17, 2023
- Japan to Map Out Substantive Policy to Solve Pharma Industry Issues: Minister
April 14, 2023
- Lower House Clears Bill to Amend Next-Gen Medical Infrastructure Law
April 14, 2023
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Ultomiris’ NMOSD Nod Up for Advisory Panel Review on April 26
April 13, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…